comparemela.com

Retrieved June News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.